Slingshot members are tracking this event:

Amgen Announces Erenumab (AMG 334) Significantly Reduces Patients' Monthly Migraine Days In Phase 2 Study For The Prevention Of Chronic Migraine

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
AMGN Community voting in process

Additional Information

Additional Relevant Details At baseline, patients enrolled in this study were experiencing approximately 18 migraine days per month. Patients were randomized to receive either placebo, or one of two erenumab doses — 70 mg or 140 mg — subcutaneously, once monthly. Patients experienced a 6.6-day reduction from baseline in monthly migraine days in each of the erenumab treatment arms as compared to a 4.2-day reduction in the placebo arm, a statistically significant reduction in each erenumab treatment arm.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 08, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Chronic Migraine, Amg 334, Erenumab, Primary Endpoint, Episodic Migraine Data